Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: neostigmine Clear all
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

NCT03923556
View directory record Official record
Conditions
Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage

NCT00745095
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Neostigmine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 2, 2026, 4:51 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Comparison of Sugammadex and Neostigmine During PACU Stay

NCT04096144
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neuromuscular Blocking Agents
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 2, 2026, 4:51 PM EDT
Terminated Phase 4 Interventional Results available

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

NCT05256901
View directory record Official record
Conditions
Appendicitis, Surgery
Interventions
Sugammadex, Neostigmine/Glycopyrrolate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

NCT03579589
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex vs Neostigmine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

NCT03112993
View directory record Official record
Conditions
Spine Surgery
Interventions
sugammadex, Neostigmine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 2, 2026, 4:51 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Use of High Resolution Colonic Manometry in Studying Motility

NCT02574611
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
Neostigmine, Glycopyrrolate, Saline (Placebo), High Resolution Colonic Manometry
Drug · Other · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

NCT04570150
View directory record Official record
Conditions
Anesthesia
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 2, 2026, 4:51 PM EDT
Not listed Phase 4 Interventional

Neostigmine Route for Acute Colonic Pseudo Obstruction

NCT04951726
View directory record Official record
Conditions
Ogilvie Syndrome
Interventions
Neostigmine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Early Phase 1 Interventional

Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI

NCT02370862
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 4:51 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 2, 2026, 4:51 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Sugammadex in Outpatient Urological Procedures

NCT03138967
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Interventions
Rocuronium, Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923
View directory record Official record
Conditions
Surgery, Coronary Artery Disease
Interventions
Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

NCT03116997
View directory record Official record
Conditions
Surgery
Interventions
Neostigmine+glycopyrrolate, Sugammadex
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional

Incidence and Severity of Residual Neuromuscular Blockade

NCT02660398
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Standardized NMBD Management
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex To IMprove Bowel Function

NCT04546672
View directory record Official record
Conditions
Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Not applicable Interventional Results available

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

NCT00633256
View directory record Official record
Conditions
Smoking
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 2, 2026, 4:51 PM EDT
Active, not recruiting Phase 3 Interventional

Neostigmine and Glycopyrrolate by Iontophoresis

NCT06351995
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520
View directory record Official record
Conditions
Paralysis
Interventions
neostigmine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

NCT03322657
View directory record Official record
Conditions
Neuromuscular Blockade, Anesthesia
Interventions
Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

NCT05985343
View directory record Official record
Conditions
Hernia, Ventral, Ileus
Interventions
Neostigmine / Glycopyrrolate, Sugammadex
Drug
Lead sponsor
Clayton Petro
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 2, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 2, 2026, 4:51 PM EDT